tirzepatide and glaucoma Comparative ocular outcomes of versus other anti-obesity medications in people with obesity Study link: https://www.ajo.com/article/S0002-9394(25)00653-1/abstract, #glaucoma #eye

The trial showed that a higher proportion of patients treated with tirzepatide achieved glycemic targets, with 82% to 86% reaching an HbA1c level of less than 7.0% and 27% to 46% reaching an HbA1c level of less than 5.7%

This effect was slightly attenuatedbut remained statistically significantwhen semaglutide was compared against other GLP-1 receptor agonists

This antioxidant-rich treatment detoxifies the body, boosts the immune system, and supports liver function, ensuring overall health and vitality

Phase 3 data showed lower rates of nausea and vomiting compared to GLP-1 therapiespotentially better tolerated for some patients